{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:30:37Z","timestamp":1793154637947,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is a lack of prospective clinical trials on the therapy of salivary gland cancer (SGC) due the rarity and large variety of histological subtypes. This study aimed to compare overall survival (OS) after primary surgery of SGC followed by postoperative radiotherapy (PORT) versus radiochemotherapy (PORCT) in curative intent. A systematic review and meta-analysis were performed on studies reporting OS after the two postoperative therapy modalities using hazard ratios (HRs) or allowing to calculate the HRs from the data. These studies were identified from PubMed, Web of Science, and Cochrane Library databases until October 2024. Pooled HR with 95% confidence interval (CI) is reported with random-effects or fixed-effects models. The search yielded 1,074 publications, of which 11 retrospective clinical studies with 26,612 adult patients could be included. None of the studies found a statistically significant difference between PORT and PORCT. Likewise, this meta-analysis revealed no statistically significant difference between PORT and PORCT. The pooled HR based on a common effect model was 1.065 (CI: 0.998\u20131.137) with low between study heterogeneity (I\u00b2=24.1%) and heterogeneity variance \u03c4\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.009. A meta-regression only revealed one factor with influence on the HR. The proportion of T4 patients in the total study shows a HR\u2009=\u20091.153 for a 10% change 95% CI: 1.014,1.314). This meta-analysis, based on a highly confounded observational setting, does not permit a reliable conclusion as to whether PORCT leads to better OS than PORT as adjuvant therapy for patients with SGC. PORCT might be beneficial for high-risk subgroups. However, this was not possible to determine in this meta-analysis as all included studies were retrospective and heterogeneous leading to a high degree of uncertainty about the therapy effects. More robust data from high-quality cohort studies or randomized controlled studies are needed. There is an urgent need for alternative and more effective multimodal treatment concepts for SGC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-52018-4","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:35:12Z","timestamp":1778088912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Postoperative radiotherapy versus postoperative radiochemotherapy after surgery of salivary gland cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Anja","family":"Wilhelmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schlattmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-0784","authenticated-orcid":false,"given":"Orlando","family":"Guntinas-Lichius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"52018_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00820-9","volume":"22","author":"NP Joshi","year":"2021","unstructured":"Joshi, N. P. & Broughman, J. R. Postoperative management of salivary gland tumors.. Curr. Treat. Options. Oncol. 22, 23. https:\/\/doi.org\/10.1007\/s11864-021-00820-9 (2021).","journal-title":"Curr. Treat. Options. Oncol."},{"key":"52018_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00405-023-08252-x","volume":"281","author":"A Scarpa","year":"2024","unstructured":"Scarpa, A. et al. Post-operative radiotherapy in adenoid cystic carcinoma of salivary glands versus surgery alone: What is the evidence about survival and local control? A systematic review and meta-analysis. Eur. Arch. Otorhinolaryngol. 281, 563\u2013571. https:\/\/doi.org\/10.1007\/s00405-023-08252-x (2024).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"52018_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132375","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. The current position of postoperative radiotherapy for salivary gland cancer: A systematic review and meta-analysis.. Cancers https:\/\/doi.org\/10.3390\/cancers16132375 (2024).","journal-title":"Cancers"},{"key":"52018_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1634\/theoncologist.10-3-215","volume":"10","author":"J Bernier","year":"2005","unstructured":"Bernier, J. & Cooper, J. S. Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?. Oncologist 10, 215\u2013224 (2005).","journal-title":"Oncologist"},{"key":"52018_CR5","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00432-015-1961-y","volume":"141","author":"O Guntinas-Lichius","year":"2015","unstructured":"Guntinas-Lichius, O. et al. Incidence, treatment, and outcome of parotid carcinoma, 1996\u20132011: A population-based study in Thuringia, Germany. J. Cancer Res. Clin. Oncol. 141, 1679\u20131688. https:\/\/doi.org\/10.1007\/s00432-015-1961-y (2015).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"52018_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","volume":"156","author":"S Arya","year":"2021","unstructured":"Arya, S., Kaji, A. H. & Boermeester, M. A. PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg. 156, 789\u2013790. https:\/\/doi.org\/10.1001\/jamasurg.2021.0546 (2021).","journal-title":"JAMA Surg."},{"key":"52018_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/pbc.25139","volume":"61","author":"S Chiaravalli","year":"2014","unstructured":"Chiaravalli, S. et al. Salivary gland carcinomas in children and adolescents: The Italian TREP project experience. Pediatr. Blood Cancer 61, 1961\u20131968. https:\/\/doi.org\/10.1002\/pbc.25139 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"52018_CR8","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (2025)."},{"key":"52018_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16. https:\/\/doi.org\/10.1186\/1745-6215-8-16 (2007).","journal-title":"Trials"},{"key":"52018_CR10","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1128\/aac.48.8.2787-2792.2004","volume":"48","author":"SL Spruance","year":"2004","unstructured":"Spruance, S. L., Reid, J. E., Grace, M. & Samore, M. Hazard ratio in clinical trials. Antimicrob. Agents Chemother. 48, 2787\u20132792. https:\/\/doi.org\/10.1128\/aac.48.8.2787-2792.2004 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52018_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B 34, 186\u2013202 (1972).","journal-title":"J. R. Stat. Soc. B"},{"key":"52018_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi, S., R\u00fccker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 22, 153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117 (2019).","journal-title":"Evid. Based Ment. Health"},{"key":"52018_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03 (2010).","journal-title":"J. Stat. Softw."},{"key":"52018_CR14","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T. & Ebert, D. D. dmetar: Companion R Package For The Guide \u2018Doing Meta-Analysis in R\u2019. R package version 0.1.0. (2019)."},{"key":"52018_CR15","doi-asserted-by":"publisher","unstructured":"Schwarzer, G., Carpenter, J. R. & R\u00fccker, G. Statistical Methods for Sensitivity Analysis in Meta-Analysis - Package \u2018metasens\u2019, https:\/\/link.springer.com\/book\/, https:\/\/doi.org\/10.1007\/978-3-319-21416-0%3E (2019).","DOI":"10.1007\/978-3-319-21416-0%3E"},{"key":"52018_CR16","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung, J. & Knapp, G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat. Med. 20, 3875\u20133889. https:\/\/doi.org\/10.1002\/sim.1009 (2001).","journal-title":"Stat. Med."},{"key":"52018_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186 (2002).","journal-title":"Stat. Med."},{"key":"52018_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629 (1997).","journal-title":"BMJ"},{"key":"52018_CR19","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat, B., Mah\u00e9, C., Pignon, J. P. & Hill, C. A graphical method for exploring heterogeneity in meta-analyses: Application to a meta-analysis of 65 trials. Stat. Med. 21, 2641\u20132652. https:\/\/doi.org\/10.1002\/sim.1221 (2002).","journal-title":"Stat. Med."},{"key":"52018_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jrsm.11","volume":"1","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. & Cheung, M. W. Outlier and influence diagnostics for meta-analysis. Res. Synth. Methods 1, 112\u2013125. https:\/\/doi.org\/10.1002\/jrsm.11 (2010).","journal-title":"Res. Synth. Methods"},{"key":"52018_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaoto.2016.2168","volume":"142","author":"A Amini","year":"2016","unstructured":"Amini, A. et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: Data from the National Cancer Data Base. JAMA Otolaryngol. Head Neck Surg. 142, 1100\u20131110. https:\/\/doi.org\/10.1001\/jamaoto.2016.2168 (2016).","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"52018_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/hed.24984","volume":"40","author":"S Cheraghlou","year":"2018","unstructured":"Cheraghlou, S. et al. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head Neck 40, 1343\u20131355. https:\/\/doi.org\/10.1002\/hed.24984 (2018).","journal-title":"Head Neck"},{"key":"52018_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/hed.27222","volume":"45","author":"AJ Gordon","year":"2023","unstructured":"Gordon, A. J. et al. Adoption of adjuvant chemotherapy in high-risk salivary gland malignancies. Head Neck 45, 167\u2013177. https:\/\/doi.org\/10.1002\/hed.27222 (2023).","journal-title":"Head Neck"},{"key":"52018_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-0039-1683437","volume":"81","author":"SJ Torabi","year":"2020","unstructured":"Torabi, S. J. et al. Multi-modality treatment and survival in sinonasal minor salivary gland tumors. Journal of Neurological Surgery Part B: Skull Base 81, 198\u2013205. https:\/\/doi.org\/10.1055\/s-0039-1683437 (2020).","journal-title":"Journal of Neurological Surgery Part B: Skull Base"},{"key":"52018_CR25","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/hed.27845","volume":"46","author":"F Yan","year":"2024","unstructured":"Yan, F. et al. Timing of postoperative radiation therapy for major salivary gland cancers. Head Neck 46, 2861\u20132869. https:\/\/doi.org\/10.1002\/hed.27845 (2024).","journal-title":"Head Neck"},{"key":"52018_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25468-9","volume":"12","author":"NW Kang","year":"2022","unstructured":"Kang, N. W. et al. No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer. Sci. Rep. 12, 20862. https:\/\/doi.org\/10.1038\/s41598-022-25468-9 (2022).","journal-title":"Sci. Rep."},{"key":"52018_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.195","volume":"3","author":"BE Onderdonk","year":"2020","unstructured":"Onderdonk, B. E. et al. Adjuvant treatment for high-risk salivary gland malignancies and prognostic stratification based on a 20-year single institution experience. Health Sci. Rep. 3, e195. https:\/\/doi.org\/10.1002\/hsr2.195 (2020).","journal-title":"Health Sci. Rep."},{"key":"52018_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05719-0","volume":"150","author":"Z Qiu","year":"2024","unstructured":"Qiu, Z. et al. Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma. J. Cancer Res. Clin. Oncol. 150, 195. https:\/\/doi.org\/10.1007\/s00432-024-05719-0 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"52018_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/hed.24172","volume":"38","author":"T Tanvetyanon","year":"2016","unstructured":"Tanvetyanon, T. et al. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck 38, 863\u2013870. https:\/\/doi.org\/10.1002\/hed.24172 (2016).","journal-title":"Head Neck"},{"key":"52018_CR30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.2147\/cmar.S283494","volume":"13","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Outcome of adenoid cystic carcinoma of head and neck after postoperative intensity modulation radiotherapy: A single institution study. Cancer Manag. Res. 13, 2411\u20132417. https:\/\/doi.org\/10.2147\/cmar.S283494 (2021).","journal-title":"Cancer Manag. Res."},{"key":"52018_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C van Herpen","year":"2022","unstructured":"van Herpen, C. et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 7, 100602. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100602 (2022).","journal-title":"ESMO Open"},{"key":"52018_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger, J. L. et al. Management of salivary gland malignancy: ASCO guideline. J. Clin. Oncol. 39, 1909\u20131941. https:\/\/doi.org\/10.1200\/JCO.21.00449 (2021).","journal-title":"J. Clin. Oncol."},{"key":"52018_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1264287","volume":"13","author":"LD Locati","year":"2023","unstructured":"Locati, L. D. et al. Current management and future challenges in salivary glands cancer. Front. Oncol. 13, 1264287. https:\/\/doi.org\/10.3389\/fonc.2023.1264287 (2023).","journal-title":"Front. Oncol."},{"key":"52018_CR34","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/hed.26727","volume":"43","author":"WT Turchan","year":"2021","unstructured":"Turchan, W. T., Korpics, M. C., Rooney, M., Koshy, M. & Spiotto, M. T. Impact of anatomic site of distant metastasis on survival in salivary gland cancers. Head Neck. 43, 2589\u20132601. https:\/\/doi.org\/10.1002\/hed.26727 (2021).","journal-title":"Head Neck"},{"key":"52018_CR35","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00405-021-07024-9","volume":"279","author":"V Freitag","year":"2022","unstructured":"Freitag, V. et al. High-grade salivary gland cancer: Is surgery followed by radiotherapy an adequate treatment to reach tumor control? Results from a tertiary referral centre focussing on incidence and management of distant metastases. Eur. Arch. Otorhinolaryngol. 279, 2553\u20132563. https:\/\/doi.org\/10.1007\/s00405-021-07024-9 (2022).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"52018_CR36","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00405-020-06393-x","volume":"278","author":"A R\u00fchle","year":"2021","unstructured":"R\u00fchle, A. et al. Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: Results from a matched-pair analysis of a rare disease. Eur. Arch. Otorhinolaryngol. 278, 2537\u20132548. https:\/\/doi.org\/10.1007\/s00405-020-06393-x (2021).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"52018_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11060906","author":"KJ Taylor","year":"2023","unstructured":"Taylor, K. J. et al. Serious long-term effects of head and neck cancer from the survivors\u2019 point of view.. Healthcare https:\/\/doi.org\/10.3390\/healthcare11060906 (2023).","journal-title":"Healthcare"},{"key":"52018_CR38","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/ijc.34861","volume":"154","author":"KJ Taylor","year":"2024","unstructured":"Taylor, K. J. et al. Long-term health-related quality of life in head and neck cancer survivors: A large multinational study. Int. J. Cancer 154, 1772\u20131785. https:\/\/doi.org\/10.1002\/ijc.34861 (2024).","journal-title":"Int. J. Cancer"},{"key":"52018_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103679","volume":"174","author":"M Fasano","year":"2022","unstructured":"Fasano, M. et al. Immunotherapy for head and neck cancer: Present and future. Crit. Rev. Oncol. Hematol. 174, 103679. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103679 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"52018_CR40","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","volume":"29","author":"JL Vos","year":"2023","unstructured":"Vos, J. L. et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial. Nat. Med. 29, 3077\u20133089. https:\/\/doi.org\/10.1038\/s41591-023-02518-x (2023).","journal-title":"Nat. Med."},{"key":"52018_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","volume":"25","author":"GJ Hanna","year":"2020","unstructured":"Hanna, G. J. et al. The benefits of adjuvant Trastuzumab for HER-2-Positive salivary gland cancers. Oncologist 25, 598\u2013608. https:\/\/doi.org\/10.1634\/theoncologist.2019-0841 (2020).","journal-title":"Oncologist"},{"key":"52018_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","volume":"110","author":"W van Boxtel","year":"2019","unstructured":"van Boxtel, W. et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur. J. Cancer 110, 62\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.035 (2019).","journal-title":"Eur. J. Cancer"},{"key":"52018_CR43","unstructured":"Guntinas-Lichius, O. et al. Salivary Gland Carcinomas. Onkopedia guidelines. (2024). https:\/\/www.onkopedia.com\/en\/onkopedia\/guidelines\/salivary-gland-carcinomas\/@@guideline\/html\/index.html"},{"key":"52018_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0617-7","volume":"11","author":"CE Hsieh","year":"2016","unstructured":"Hsieh, C. E. et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat. Oncol. 11, 47. https:\/\/doi.org\/10.1186\/s13014-016-0617-7 (2016).","journal-title":"Radiat. Oncol."},{"key":"52018_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225583","author":"W Yan","year":"2022","unstructured":"Yan, W. et al. Postoperative chemoradiotherapy versus radiotherapy alone in major salivary gland cancers: A stratified study based on the external validation of the distant metastasis risk score model.. Cancers https:\/\/doi.org\/10.3390\/cancers14225583 (2022).","journal-title":"Cancers"},{"key":"52018_CR46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00405-022-07599-x","volume":"280","author":"D Zhang","year":"2023","unstructured":"Zhang, D., Li, L., Wen, T. & Ma, F. Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: A large-scale cohort study. Eur. Arch. Otorhinolaryngo. 280, 409\u2013417. https:\/\/doi.org\/10.1007\/s00405-022-07599-x (2023).","journal-title":"Eur. Arch. Otorhinolaryngo."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52018-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:07:57Z","timestamp":1778425677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52018-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52018"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52018-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval and patient informed consent were not required for a meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"During the preparation of this work the authors did not use such a technology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"14426"}}